Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

HCM vs AVDL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVDL Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)

AVDL Overall Winner 6-Pillar Tally: HCM 1 – 4 AVDL (1 Tie) Matrix Metrics: HCM 3 – 7 AVDL

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over HUTCHMED (China) Limited (HCM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HCM carries a Unified Composite Score of 38.1/100 (SELL) at $13.22 (N/M Forward P/E, -6.3% operating margin), whereas AVDL carries 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HCM vs AVDL
HCM NASDAQ
HUTCHMED (China) Limited American Depositary Shares
Pharmaceutical Preparations
$13.22
-1.71% 1D
Market Cap $2.3B
TTM Revenue $549M
Forward P/E N/M
Beta / 30D Vol 0.64β · 45% Vol
Unified Composite Score
38.1 / 100 SELL
Tech 31.0 Fund 44.0 Flow 50.0 Mom 56.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 38.5 · SMA20: $14.15 · SMA50: $14.11
AVDL NASDAQ Head-to-Head Winner
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
TTM Revenue $249M
Forward P/E 28.8x
Beta / 30D Vol 0.14β · 2% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50

6-Pillar Scorecard Institutional Category Breakdown (HCM 1 – 4 AVDL)

Columns: Metric · HCM · AVDL
1. Valuation Multiples AVDL
Forward P/E N/M 28.8x
Trailing P/E 134.0x 16.8x
PEG Ratio N/M 0.07x
EV / Revenue 4.2x 8.5x
2. Growth & Scale AVDL
Revenue Growth (YoY) +0.2% +54.9%
Earnings Growth (YoY) -96.5% +0.0%
TTM Revenue (USD) $549M $249M
Market Cap $2.3B $2.1B
3. Profitability & Quality AVDL
Gross Margin 13.3% 94.9%
Operating Margin -6.3% 2.5%
Net Profit Margin 3.3% -0.1%
Return on Equity (ROE) 1.5% -0.3%
4. Balance Sheet & Cash Flow AVDL
Cash Generation (TTM) -$21M EBITDA $2.7M EBITDA
Cash Flow Margin -3.7% EBITDA Mgn 1.1% EBITDA Mgn
Net Cash / Leverage $7.25 Book/Sh · 1.5% ROE $1.01 Book/Sh · -0.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 82.7% (73rd %ile) 2.4% (<1st %ile)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat HCM
OpEx & R&D Intensity 19.6% of Rev ($108M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HCM (3) vs AVDL (7)
Institutional Metric HCM AVDL Criterion Row Edge
Market Capitalization
Scale
$2.3B $2.1B Larger Scale HCM
Trailing P/E Ratio
Valuation
134.0x 16.8x Lower Multiple AVDL
Forward P/E Ratio
Valuation
N/M 28.8x Lower Multiple AVDL
Revenue Growth (YoY)
Growth
+0.2% +54.9% Higher Growth AVDL
Operating Margin (TTM)
Profitability
-6.3% 2.5% Higher Margin AVDL
Net Profit Margin
Profitability
3.3% -0.1% Higher Margin HCM
Return on Equity (ROE)
Capital Efficiency
1.5% -0.3% Higher ROE HCM
52-Week Range Position
Momentum
53% ($10–$16) 89% ($6–$24) Stronger Trend AVDL
Beta / 30D Volatility
Risk Regime
0.64β · 45% Vol 0.14β · 2% Vol Lower Realized Risk AVDL
Unified Institutional Score
Composite Signal
38.1 / 100 (SELL) 62.9 / 100 (BUY) Higher Composite AVDL
Trailing 12M Revenue (USD)
Operating Scale
$549M $249M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
13.3% 94.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 4.2x EV/Rev 0.07x PEG · 8.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M EBITDA ($7.25 Book/Sh · 1.5% ROE) $2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HCM +0.56 pp
HCM: +1.21% · AVDL: +0.65%
3M Horizon HCM +8.74 pp
HCM: +3.07% · AVDL: -5.67%
6M Horizon HCM +8.74 pp
HCM: +3.07% · AVDL: -5.67%
1Y Horizon HCM +8.74 pp
HCM: +3.07% · AVDL: -5.67%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HCM vs AVDL. Trailing 12-month operating profitability (HCM -6.3% vs AVDL 2.5%) and valuation multiples (HCM N/M vs AVDL 28.8x Forward P/E) are benchmarked directly in Pillar 4 below.

HCM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$549M
Gross Margin13.3%
Op. Margin-6.3%
ROE / Fwd P/E1.5% · N/M
AVDL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$249M
Gross Margin94.9%
Op. Margin2.5%
ROE / Fwd P/E-0.3% · 28.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HCM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 82.7%
IV Percentile 73rd %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HCM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AVDL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 2.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVDL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HCM Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.3B market capitalization and -6.3% operating margin.
OpEx & R&D Reinvestment 19.6% of Rev ($108M)
90D Engineering Disclosures 0 Published
AVDL Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ HCM vs AVDL Key Questions & Quantitative Answers

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over HUTCHMED (China) Limited (HCM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HCM carries a Unified Composite Score of 38.1/100 (SELL) at $13.22 (N/M Forward P/E, -6.3% operating margin), whereas AVDL carries 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin). Technically, HCM sits in a Neutral phase (RSI 38.5, UNCLASSIFIED options structure) and AVDL sits in a Markup phase (RSI 62.3, UNCLASSIFIED options structure).

AVDL leads the Growth & Scale pillar: HCM posts +0.2% YoY revenue growth and -96.5% YoY earnings growth on $549M TTM revenue (13.3% gross margin, -6.3% operating margin), compared with AVDL at +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin). On trailing 12-month operating scale, HCM generates $549M in USD-normalized revenue versus $249M for AVDL. In operating R&D and SG&A reinvestment, HCM deploys 19.6% of Rev ($108M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVDL.

AVDL screens cheaper on headline valuation multiples. HCM trades at N/M Forward P/E, 134.0x Trailing P/E, N/M PEG, and 4.2x EV/Revenue (-3.7% EBITDA margin), whereas AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HCM (1.5% ROE) versus AVDL (-0.3% ROE) capital efficiency.

In options market volatility and institutional positioning, HCM carries 82.7% implied volatility (73rd %ile, Elevated (60th–80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.64β · 45% Vol realized risk). By comparison, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.